Cardlytics Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | -$0.103 |
| EPS actual | -$0.0700 |
| EPS Surprise | 32.26% |
| Revenue estimate | 56.318M |
| Revenue actual | 52.031M |
| Revenue Surprise | -7.61% |
| Release date | Aug 06, 2025 |
| EPS estimate | -$0.160 |
| EPS actual | -$0.130 |
| EPS Surprise | 18.75% |
| Revenue estimate | 64.016M |
| Revenue actual | 63.249M |
| Revenue Surprise | -1.20% |
| Release date | May 07, 2025 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.210 |
| EPS Surprise | 22.22% |
| Revenue estimate | 58.012M |
| Revenue actual | 61.898M |
| Revenue Surprise | 6.70% |
| Release date | Mar 12, 2025 |
| EPS estimate | -$0.240 |
| EPS actual | -$0.310 |
| EPS Surprise | -29.17% |
| Revenue estimate | 61.256M |
| Revenue actual | 73.997M |
| Revenue Surprise | 20.80% |
Last 4 Quarters for Cardlytics
Below you can see how CDLX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Mar 12, 2025 |
| Price on release | $1.98 |
| EPS estimate | -$0.240 |
| EPS actual | -$0.310 |
| EPS surprise | -29.17% |
| Date | Price |
|---|---|
| Mar 06, 2025 | $2.24 |
| Mar 07, 2025 | $2.00 |
| Mar 10, 2025 | $1.81 |
| Mar 11, 2025 | $2.02 |
| Mar 12, 2025 | $1.98 |
| Mar 13, 2025 | $2.07 |
| Mar 14, 2025 | $2.47 |
| Mar 17, 2025 | $2.38 |
| Mar 18, 2025 | $2.35 |
| 4 days before | -11.61% |
| 4 days after | 18.69% |
| On release day | 4.55% |
| Change in period | 4.91% |
| Release date | May 07, 2025 |
| Price on release | $2.16 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.210 |
| EPS surprise | 22.22% |
| Date | Price |
|---|---|
| May 01, 2025 | $1.51 |
| May 02, 2025 | $1.84 |
| May 05, 2025 | $2.14 |
| May 06, 2025 | $2.15 |
| May 07, 2025 | $2.16 |
| May 08, 2025 | $1.90 |
| May 09, 2025 | $1.94 |
| May 12, 2025 | $2.17 |
| May 13, 2025 | $2.10 |
| 4 days before | 43.05% |
| 4 days after | -2.78% |
| On release day | -12.04% |
| Change in period | 39.07% |
| Release date | Aug 06, 2025 |
| Price on release | $1.76 |
| EPS estimate | -$0.160 |
| EPS actual | -$0.130 |
| EPS surprise | 18.75% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $2.04 |
| Aug 01, 2025 | $1.88 |
| Aug 04, 2025 | $1.96 |
| Aug 05, 2025 | $1.84 |
| Aug 06, 2025 | $1.76 |
| Aug 07, 2025 | $1.30 |
| Aug 08, 2025 | $1.18 |
| Aug 11, 2025 | $1.10 |
| Aug 12, 2025 | $1.25 |
| 4 days before | -13.73% |
| 4 days after | -28.98% |
| On release day | -26.14% |
| Change in period | -38.73% |
| Release date | Nov 05, 2025 |
| Price on release | $1.76 |
| EPS estimate | -$0.103 |
| EPS actual | -$0.0700 |
| EPS surprise | 32.26% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $1.90 |
| Oct 31, 2025 | $1.94 |
| Nov 03, 2025 | $1.90 |
| Nov 04, 2025 | $1.74 |
| Nov 05, 2025 | $1.76 |
| Nov 06, 2025 | $1.26 |
| Nov 07, 2025 | $1.41 |
| Nov 10, 2025 | $1.43 |
| Nov 11, 2025 | $1.47 |
| 4 days before | -7.37% |
| 4 days after | -16.48% |
| On release day | -28.41% |
| Change in period | -22.63% |
Cardlytics Earnings Call Transcript Summary of Q3 2025
Cardlytics reported Q3 2025 results impacted by content restrictions from its largest financial-institution (FI) partner that blocked roughly one-third of expected billings. Management mitigated much of the impact by shifting volume to other banks in the network, expanding supply and engagement initiatives (e.g., Double Days, category-level offers), and growing non-FI publisher efforts through the Cardlytics Rewards Platform (CRP) including a signed partnership with OpenTable. Key financials: Q3 billings $89.2M (-20.3% YoY), revenue $52.0M (-22.4% YoY), adjusted contribution $30.0M (-17.5% YoY), adjusted EBITDA positive $3.2M (improvement of $5.0M YoY). MQUs were 230.3M (+21% YoY) and ACPU fell to $0.11 (-31% YoY). The U.K. business grew 22% YoY. The company completed repayment of its 2020 convertible notes, reduced headcount by ~30% and expects $26M in annualized cash savings from recent cost actions (total $50M in reductions year-to-date). Guidance for Q4 2025: billings $86M–$96M, revenue $51.1M–$59.1M, adjusted contribution $29M–$35M, adjusted EBITDA $0.9M–$7.9M. Management expects adjusted EBITDA to be positive for Q4 and full-year 2025, intends to prioritize supply diversification (CRP and new FI ramps), omnichannel performance offerings, and operational discipline to return to growth in 2026. Investors should watch: pace of reallocation of blocked volume to other FI partners, CRP launches and monetization cadence (OpenTable and two other partners), improvement in revenue-to-billings margin and adjusted contribution margin (now among the highest to date), and realized cost savings versus guidance.
Sign In
Buy CDLX